Biocon’s Q3 revenue and EBITDA missed estimates, while profit rose sharply on a low base despite a ₹293 crore exceptional ...

Biocon posts 9% rise in Q3FY26 revenue to Rs 4,173 crore; net profit jumps to Rs 143.8 crore on strong generics and ...

Thursday’s earnings-heavy session saw results from HUL, Hindalco, ONGC, Coal India, Biocon and Bharat Forge, among others, ...

Biocon Limited on Thursday reported a 5.7-fold year-on-year (YoY) increase in consolidated net profit attributable to the shareholders of the company, reaching ₹144 crore for the quarter ended ...

Biocon on Thursday reported over five-fold jump in consolidated net profit to Rs 144 crore for the third quarter ended ...

Firms including Biocon, Lupin, Petronet LNG, IRCTC, Indraprastha Gas, Schneider Electric and are also to release their October-December earnings today ...

The biosimilar fracas targeting AbbVie’s megablockbuster Humira is taking shape. But to Biocon Biologics CEO Shreehas Tambe, the battle doesn’t solely revolve around market share. Humira, also known ...

Biocon reports a five-fold jump in Q3 net profit to Rs 144 crore, driven by generics and biosimilars. Revenue increased to Rs ...

Hindustan Unilever has already announced its results, reporting a slight beat on profit while revenues were largely in line.

Biocon’s insulin copycat aspart hit another roadblock as the FDA issued a complete response letter (CRL), saying the Malaysia production facility still must undergo a pre-approval inspection to ...

Biocon Biologics has been positioning itself to become a global player in biosimilar drugs. Viatris, a longtime partner to Biocon, is charting a course for its future that does not include biosimilars ...

S&P Global Ratings has upgraded the long-term issuer credit rating of Biocon Biologics Limited to 'BB+' from 'BB' and revised ...